Abemaciclib vs Dalpiciclib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: CDK4 and CDK6 · full HR+/HER2- Metastatic Breast Cancer pipeline
Abemaciclib · Verzenio
Marketed by Eli Lilly
NCT02107703 · Phase 3 · active, not recruiting
This was a randomized, double-blind, placebo-controlled phase 3 trial of 669 women. The primary endpoint, progression-free survival, was met with a clear, statistically significant advantage for abemaciclib plus fulvestrant.
Next expected readout: December 2026 · NCT05305924 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4) (met)
Result source: NCT02107703
Dalpiciclib
Marketed by Jiangsu Hengrui Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT04993430 (registry estimate)
No aligned efficacy figure on record for this race.
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Abemaciclib | Dalpiciclib |
|---|---|---|
| PFS, median | 16.4 vs 9.3+7.1 vs placeboNCT0210770311 other results
| —Trial running · NCT06612814 |
| OS, median | 45.8 vs 37.3+8.5 vs placeboNCT021077036 other results
| —Trial running · NCT06612814 |
| ORR | 35.2% vs 16.1%+19.1 vs placeboNCT021077034 other results
| —Trial running · NCT06612814 |
| Clinical benefit rate | 72.2% vs 56.1%+16.1 vs placeboNCT021077038 other results
| —Trial running · NCT06612814 |
PFS, median
- Abemaciclib
- 16.4 vs 9.3+7.1 vs placeboNCT02107703
11 other results
- 8.3 vs 5.7 NCT02675231
- 5.7 vs 5.7 NCT02675231
- 6.3 vs 1.9 NCT03280563
- 6 NCT02102490
- 2.1 NCT03099174
- 13.6 NCT03099174
- 33.1 NCT03099174
- 2.1 NCT02308020
- 4.4 NCT02308020
- 1.4 NCT02308020
- 1.2 NCT02308020
- Dalpiciclib
- —Trial running · NCT06612814
OS, median
- Abemaciclib
- 45.8 vs 37.3+8.5 vs placeboNCT02107703
6 other results
- 26.7 vs 26.0 NCT03280563
- 22.3 NCT02102490
- 10.1 NCT02308020
- 13.4 NCT02308020
- 7.1 NCT02308020
- 2.9 NCT02308020
- Dalpiciclib
- —Trial running · NCT06612814
ORR
- Abemaciclib
- 35.2% vs 16.1%+19.1 vs placeboNCT02107703
4 other results
- 26.3% vs 10% NCT03280563
- 19.7% NCT02102490
- 32.9% vs 13.9% NCT02675231
- 13.9% vs 13.9% NCT02675231
- Dalpiciclib
- —Trial running · NCT06612814
Clinical benefit rate
- Abemaciclib
- 72.2% vs 56.1%+16.1 vs placeboNCT02107703
8 other results
- 58.2% vs 38% NCT02675231
- 45.6% vs 38% NCT02675231
- 42.1% vs 15% NCT03280563
- 42.4% NCT02102490
- 13% NCT02308020
- 26.9% NCT02308020
- 26.1% NCT02308020
- 9.1% NCT02308020
- Dalpiciclib
- —Trial running · NCT06612814
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Dalpiciclib: no structured comparison results are available for HR+/HER2- Metastatic Breast Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Abemaciclib: 4 of 4 rows · Dalpiciclib: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Abemaciclib |
|---|---|
| Dropout rate | 25.6%a NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 23 more results5.3% NCT02102490 · Phase 2 31.7%Abemaciclib + Fulvestrant NCT04707196 · Phase 4 · registry result, not featured evidence · combination 21.2%Abemaciclib + NSAI NCT04707196 · Phase 4 · registry result, not featured evidence · combination 10.1%150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 6.3%150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 16.7%200 mg NCT03703466 · Phase 2 · registry result, not featured evidence 8.3%200 mg NCT03703466 · Phase 2 · registry result, not featured evidence 25%200 mg NCT03703466 · Phase 2 · registry result, not featured evidence —Part A Abemaciclib: HR+, HER2+ Bre NCT02308020 · Phase 2 · registry result, not featured evidence · combination 34.5%Part B Abemaciclib: HR+, HER2- Bre NCT02308020 · Phase 2 · registry result, not featured evidence · combination 33.3%Part C Abemaciclib: Surgical Resec NCT02308020 · Phase 2 · registry result, not featured evidence —Part D Abemaciclib: NSCLC NCT02308020 · Phase 2 · registry result, not featured evidence 17.4%Part E Abemaciclib: Melanoma NCT02308020 · Phase 2 · registry result, not featured evidence —Part F: Abemaciclib HR+ Breast Can NCT02308020 · Phase 2 · registry result, not featured evidence · combination 17.5% NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —a NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 23 more results— NCT02102490 · Phase 2 3.2%Abemaciclib + Fulvestrant NCT04707196 · Phase 4 · registry result, not featured evidence · combination 1.5%Abemaciclib + NSAI NCT04707196 · Phase 4 · registry result, not featured evidence · combination —150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination —150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination —200 mg NCT03703466 · Phase 2 · registry result, not featured evidence —200 mg NCT03703466 · Phase 2 · registry result, not featured evidence —200 mg NCT03703466 · Phase 2 · registry result, not featured evidence —Part A Abemaciclib: HR+, HER2+ Bre NCT02308020 · Phase 2 · registry result, not featured evidence · combination —Part B Abemaciclib: HR+, HER2- Bre NCT02308020 · Phase 2 · registry result, not featured evidence · combination —Part C Abemaciclib: Surgical Resec NCT02308020 · Phase 2 · registry result, not featured evidence —Part D Abemaciclib: NSCLC NCT02308020 · Phase 2 · registry result, not featured evidence —Part E Abemaciclib: Melanoma NCT02308020 · Phase 2 · registry result, not featured evidence —Part F: Abemaciclib HR+ Breast Can NCT02308020 · Phase 2 · registry result, not featured evidence · combination — NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination 0%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 14.3%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 14.3%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 18.2%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 12.9%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 25%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 19.2%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 20%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination |
| Serious AEs | 29.3%a NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 23 more results25% NCT02102490 · Phase 2 7.9%Abemaciclib + Fulvestrant NCT04707196 · Phase 4 · registry result, not featured evidence · combination 6.6%Abemaciclib + NSAI NCT04707196 · Phase 4 · registry result, not featured evidence · combination 19.5%150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 30.8%150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 12.5%200 mg NCT03703466 · Phase 2 · registry result, not featured evidence 33.3%200 mg NCT03703466 · Phase 2 · registry result, not featured evidence 21.7%200 mg NCT03703466 · Phase 2 · registry result, not featured evidence 22.2%Part A Abemaciclib: HR+, HER2+ Bre NCT02308020 · Phase 2 · registry result, not featured evidence · combination 27.6%Part B Abemaciclib: HR+, HER2- Bre NCT02308020 · Phase 2 · registry result, not featured evidence · combination 33.3%Part C Abemaciclib: Surgical Resec NCT02308020 · Phase 2 · registry result, not featured evidence 28.6%Part D Abemaciclib: NSCLC NCT02308020 · Phase 2 · registry result, not featured evidence 17.4%Part E Abemaciclib: Melanoma NCT02308020 · Phase 2 · registry result, not featured evidence 41.2%Part F: Abemaciclib HR+ Breast Can NCT02308020 · Phase 2 · registry result, not featured evidence · combination 35.9% NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination 0%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 57.1%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 57.1%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 33.3%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 51.6%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 37.5%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 50%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 26.7%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination |
| Most frequent reported AEs | a diarrhoea 87.1% (placebo 27.8%) neutropenia 49.7% (placebo 3.6%) nausea 49.4% (placebo 24.7%) NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 23 more resultsdiarrhoea 28.6% anaemia 22.2% fatigue 20.6% NCT04707196 · Phase 4 · registry result, not featured evidence · combination diarrhoea 29.9% neutropenia 24.8% anaemia 23.4% NCT04707196 · Phase 4 · registry result, not featured evidence · combination 150 mg + 8 mg/kg diarrhoea 77.9% fatigue 53.2% nausea 41.6% NCT02675231 · Phase 2 · registry result, not featured evidence · combination 150 mg + 8 mg/kg + 500 mg diarrhoea 79.5% fatigue 57.7% nausea 48.7% NCT02675231 · Phase 2 · registry result, not featured evidence · combination 200 mg diarrhoea 87.5% nausea 62.5% anaemia 58.3% NCT03703466 · Phase 2 · registry result, not featured evidence 200 mg diarrhoea 91.7% nausea 58.3% anaemia 41.7% NCT03703466 · Phase 2 · registry result, not featured evidence 200 mg diarrhoea 95.7% anaemia 47.8% nausea 47.8% NCT03703466 · Phase 2 · registry result, not featured evidence diarrhoea 55.6% fatigue 33.3% nausea 33.3% NCT02308020 · Phase 2 · registry result, not featured evidence · combination diarrhoea 77.6% fatigue 48.3% nausea 44.8% NCT02308020 · Phase 2 · registry result, not featured evidence · combination alanine aminotransferase increased 66.7% anaemia 44.4% diarrhoea 44.4% NCT02308020 · Phase 2 · registry result, not featured evidence diarrhoea 53.6% fatigue 39.3% nausea 28.6% NCT02308020 · Phase 2 · registry result, not featured evidence abdominal pain 21.7% diarrhoea 21.7% neutropenia 21.7% NCT02308020 · Phase 2 · registry result, not featured evidence fatigue 52.9% nausea 41.2% diarrhoea 35.3% NCT02308020 · Phase 2 · registry result, not featured evidence · combination diarrhoea 84.6% fatigue 43.6% nausea 43.6% NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination 1000 mg diarrhoea 100% decreased appetite 66.7% vomiting 66.7% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg anaemia 100% diarrhoea 100% aspartate aminotransferase increased 85.7% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg diarrhoea 85.7% asthenia 71.4% neutropenia 71.4% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg diarrhoea 90.9% nausea 66.7% neutrophil count decreased 51.5% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg diarrhoea 93.5% nausea 67.7% neutrophil count decreased 51.6% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg diarrhoea 100% nausea 75% asthenia 62.5% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg diarrhoea 61.5% nausea 61.5% decreased appetite 42.3% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg diarrhoea 93.3% asthenia 60% headache 53.3% NCT03099174 · Phase 1 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for 23 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Abemaciclib
show 3 more results
show 1 more result
show 3 more results
show 3 more results
show 2 more results
show 3 more results
show 4 more results
show 4 more results
show 8 more results
show 4 more results
show 4 more results
+ 31 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Abemaciclib's landscape · Dalpiciclib's landscape